Pancreatic Cancer Research

ResearcherRoswell Park Comprehensive Cancer CenterActive in the last 2 years

Jun Qu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1346-6809; OpenAlex author ID A5063759058. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
12
Papers, trials and grants by year

2018: 3 papers · 2019: none · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 2 papers · 2024: 4 papers

Papers 11

  1. Fibroblast growth factor receptor 1 inhibition suppresses pancreatic cancer chemoresistance and chemotherapy-driven aggressiveness. Co-author DOI 10.1016/j.drup.2024.101064↗
  2. Systems Pharmacodynamic Model of Combined Gemcitabine and Trabectedin in Pancreatic Cancer Cells. Part I: Effects on Signal Transduction Pathways Related to Tu… Co-author DOI 10.1016/j.xphs.2023.10.030↗
  3. Systems Pharmacodynamic Model of Combined Gemcitabine and Trabectedin in Pancreatic Cancer Cells. Part II: Cell Cycle, DNA Damage Response, and Apoptosis Pathw… Co-author DOI 10.1016/j.xphs.2023.10.036↗
  4. Expression of fibroblast growth factor receptor 1 correlates inversely with the efficacy of single-agent fibroblast growth factor receptor-specific inhibitors … Co-author DOI 10.1111/bph.16289↗
  5. Species-Deconvolved Proteomics for In Situ Investigation of Tumor-Stroma Interactions after Treatment of Pancreatic Cancer Patient-Derived Xenografts with Comb… Last author DOI 10.1021/acs.jproteome.3c00164↗
  6. Highly Reproducible Quantitative Proteomics Analysis of Pancreatic Cancer Cells Reveals Proteome-Level Effects of a Novel Combination Drug Therapy That Induces… Last author DOI 10.1021/acs.jproteome.3c00463↗
  7. Comparative Proteomic Analysis Identifies Key Metabolic Regulators of Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.1016/j.mcpro.2022.100409↗
  8. Pharmacodynamic modeling of synergistic birinapant/paclitaxel interactions in pancreatic cancer cells. Co-author DOI 10.1186/s12885-020-07398-9↗
  9. Multi-Scale Network Model Supported by Proteomics for Analysis of Combined Gemcitabine and Birinapant Effects in Pancreatic Cancer Cells. Co-author DOI 10.1002/psp4.12320↗
  10. Temporal Effects of Combined Birinapant and Paclitaxel on Pancreatic Cancer Cells Investigated via Large-Scale, Ion-Current-Based Quantitative Proteomics (IonS… Last author DOI 10.1074/mcp.ra117.000519↗
  11. Proteomic Analysis of Combined Gemcitabine and Birinapant in Pancreatic Cancer Cells. Co-author DOI 10.3389/fphar.2018.00084↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Robert M. Straubinger · 11 shared papers, 2018–2024 · strength 1.94
  2. Qingxiang Lin · 4 shared papers, 2022–2024 · strength 0.84
  3. William J. Jusko · 5 shared papers, 2018–2024 · strength 0.80
  4. Jin Niu · 4 shared papers, 2018–2024 · strength 0.67
  5. Xue Wang · 3 shared papers, 2018–2024 · strength 0.53
  6. Tista Roy Chaudhuri · 2 shared papers, 2024 · strength 0.45
  7. Wen Wee Ma · 2 shared papers, 2024 · strength 0.45
  8. Xin Miao · 2 shared papers, 2024 · strength 0.43
  9. Sailee Suryakant Rasam · 2 shared papers, 2022–2023 · strength 0.39
  10. Xue Wang · 1 shared paper, 2020 · strength 0.15
  11. Xu Zhu · 1 shared paper, 2018 · strength 0.11
  12. Xu Zhu · 1 shared paper, 2018 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.